In addition, they thought it was valuable in providing data to the physician they could not provide(89%), in providing additional data about their normal daily activities(96%), in providing addition data that assisted the physician with making decision about their care(93%)and in providing data that contributed to the overall management of their PD(93%).Patient outcomes:MDS UPDRS III and IV, PKG scores, and Hoehn and Yahr scale.MDS-UPDRS, Part IIIScore > 27[30]MDS-UPDRS, Part IVDyskinesiasFunctional Impact Moderate or SevereMotor fluctuations>50% time spent in off stateComplexity Moderate or SeverePKG Scores[All Patients]Total Scores(Mean±SD; Range)[Controlled Bradykinesia(BKS≤25)][Uncontrolled(BKS≥2)][Uncontrolled Dyskinesia(DKS > 9)]*Statistically significant(α≤0.05).When asked whether they would be willing to pay for the device if their insurance didn’t cover the cost, 32% of patients stated they would, 25% stated it would depend on the cost and 43% said they would not pay if their insurance did not cover the cost.A 60-year old man with 1-year history of slowed movements, rest tremor and rigidity was diagnosed with PD.Carbidopa/levodopa 1 tablet every 4-hours(QID)had been initiated and produced subtle improvements in tremor and bradykinesia according to the patient who was unable to discern shifts in on-off status.Work-up included a normal brain MRI and positive DaTscan demonstrating reduced dopamine transporter binding on the right more than the left.During visit 1, the patient reported symptoms of bradykinesia, freezing and tremor, with onset of levodopa effect in ~1 hour and no clear wearing off which he reported were “unpredictable”.
In addition, they thought it was valuable in providing data to the physician they could not provide(89%), in providing additional data about their normal daily activities(96%), in providing addition data that assisted the physician with making decision about their care(93%)and in providing data that contributed to the overall management of their PD(93%).<br>Patient outcomes:MDS UPDRS III and IV, PKG scores, and Hoehn and Yahr scale.<br>MDS-UPDRS, Part III<br>Score > 27[30]<br>MDS-UPDRS, Part IV<br>Dyskinesias<br>Functional Impact Moderate or Severe<br>Motor fluctuations<br>>50% time spent in off state<br>Complexity Moderate or Severe<br>PKG Scores[All Patients]<br>Total Scores(Mean±SD; Range)<br>[Controlled Bradykinesia(BKS≤25)]<br>[Uncontrolled(BKS≥2<br>)]<br>[Uncontrolled Dyskinesia(DKS > 9)]<br>*Statistically significant(α≤0.05).<br>When asked whether they would be willing to pay for the device if their insurance didn’t cover the cost, 32% of patients stated they would, 25% stated it would depend on the cost and 43% said they would not pay if their insurance did not cover the cost.<br>A 60-year old man with 1-year history of slowed movements, rest tremor and rigidity was diagnosed with PD.<br>Carbidopa/levodopa 1 tablet every 4-hours(QID)had been initiated and produced subtle improvements in tremor and bradykinesia according to the patient who was unable to discern shifts in on-off status.<br>Work-up included a normal brain MRI and positive DaTscan demonstrating reduced dopamine transporter binding on the right more than the left.<br>During visit 1, the patient reported symptoms of bradykinesia, freezing and tremor, with onset of levodopa effect in ~1 hour and no clear wearing off which he reported were “unpredictable”.
正在翻译中..
In addition, they thought it was valuable in providing data to the physician they could not provide(89%), in providing additional data about their normal daily activities(96%), in providing addition data that assisted the physician with making decision about their care(93%)and in providing data that contributed to the overall management of their PD(93%).<br>Patient outcomes:MDS UPDRS III and IV, PKG scores, and Hoehn and Yahr scale.<br>MDS-UPDRS, Part III<br>Score > 27[30]<br>MDS-UPDRS, Part IV<br>Dyskinesias<br>Functional Impact Moderate or Severe<br>Motor fluctuations<br>>50% time spent in off state<br>Complexity Moderate or Severe<br>PKG Scores[All Patients]<br>Total Scores(Mean±SD; Range)<br>[Controlled Bradykinesia(BKS≤25)]<br>[Uncontrolled(BKS≥2<br>)]<br>[Uncontrolled Dyskinesia(DKS > 9)]<br>*Statistically significant(α≤0.05).<br>When asked whether they would be willing to pay for the device if their insurance didn’t cover the cost, 32% of patients stated they would, 25% stated it would depend on the cost and 43% said they would not pay if their insurance did not cover the cost.<br>A 60-year old man with 1-year history of slowed movements, rest tremor and rigidity was diagnosed with PD.<br>Carbidopa/levodopa 1 tablet every 4-hours(QID)had been initiated and produced subtle improvements in tremor and bradykinesia according to the patient who was unable to discern shifts in on-off status.<br>Work-up included a normal brain MRI and positive DaTscan demonstrating reduced dopamine transporter binding on the right more than the left.<br>During visit 1, the patient reported symptoms of bradykinesia, freezing and tremor, with onset of levodopa effect in ~1 hour and no clear wearing off which he reported were “unpredictable”.
正在翻译中..